Skip to main content
Clinical Trials/NCT05338905
NCT05338905
Active, Not Recruiting
N/A

Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification (INSIGHT)

Roswell Park Cancer Institute1 site in 1 country72 target enrollmentOctober 11, 2022

Overview

Phase
N/A
Intervention
Quality-of-Life Assessment
Conditions
Head and Neck Squamous Cell Carcinoma
Sponsor
Roswell Park Cancer Institute
Enrollment
72
Locations
1
Primary Endpoint
Time to first acute care visit
Status
Active, Not Recruiting
Last Updated
3 months ago

Overview

Brief Summary

This clinical trial compares intensive symptom evaluation with supportive care to standard symptom management in patients with head and neck cancer that has not spread to other places in the body (non-metastatic). Standard symptom management involves symptom management during and after radiation therapy, using problem-focused history and physical examination followed by appropriate symptomatic management as appropriate per treating physician's discretion. Intensive symptom management with monitoring patient reported outcomes is performed among patients with metastatic cancers receiving systemic therapies and with various cancers receiving radiation therapy. This trial may help researchers determine the impact of intensive symptom surveillance in patients with non-metastatic head and neck cancers.

Detailed Description

PRIMARY OBJECTIVE: I. Using study questionnaires to determine the impact of intensive symptom evaluation with supportive care as needed per treating physician's discretion versus standard symptom management on time to first acute care visits at 3 months. SECONDARY OBJECTIVES: I. Using study questionnaires to determine the impact of intensive symptom evaluation with supportive care as needed per treating physician's discretion versus standard symptom management on (1) changes in health-related quality of life (HRQOL), financial burden, and caregiver burden from baseline, (2) time to first acute care visits at 1 or 6 month, (3) locoregional (LRF) and distant failure (DF), and (4) progression-free (PFS) and overall survival (OS) outcomes. II. Using study questionnaires to determine the impact of intensive symptom evaluation with supportive care as needed per treating physician's discretion versus standard symptom management when stratified. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP A: Patients complete a quality of life questionnaires over 10-15 minutes twice weekly (BIW) during standard of care radiation therapy and once weekly (QW) for the first month after completing standard of care radiation therapy course, and then once monthly for 6 months. GROUP B: Patients receive standard symptom management QW during standard of care radiation therapy for 6 months after completing radiation therapy course.

Registry
clinicaltrials.gov
Start Date
October 11, 2022
End Date
December 17, 2027
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • PATIENTS: Age \>= 18 years of age
  • PATIENTS: Diagnosed with biopsy-proven, non-metastatic squamous cell carcinoma of head and neck
  • PATIENTS: Scheduled to start curative-intent radiation therapy within 4 weeks
  • PATIENTS: Able to provide informed consent in English
  • PATIENTS: Able to read and write in English
  • PATIENTS: Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related assessment
  • PATIENTS' INFORMED CAREGIVER (e.g. family members, friends): They are verbally identified by eligible patients as a caregiver
  • PATIENTS' INFORMED CAREGIVER (e.g. family members, friends): They are not receiving any payment to provide care for patients
  • PATIENTS' INFORMED CAREGIVER (e.g. family members, friends): Able to provide informed consent in English
  • PATIENTS' INFORMED CAREGIVER (e.g. family members, friends): Able to read and write in English

Exclusion Criteria

  • PATIENTS: Diagnosed with metastatic head and neck cancer
  • PATIENTS: Eligible for palliative-intent radiation therapy only
  • PATIENTS: Pregnant female participants
  • PATIENTS: Unwilling or unable to follow protocol requirements
  • PATIENTS: Any condition which in the Investigator's opinion deems the participant an unsuitable candidate

Arms & Interventions

Group A (quality of life questionnaire)

Patients complete a quality of life questionnaires over 10-15 minutes BIW during standard of care radiation therapy and QW for the first month after completing standard of care radiation therapy course, and then once monthly for 6 months.

Intervention: Quality-of-Life Assessment

Group A (quality of life questionnaire)

Patients complete a quality of life questionnaires over 10-15 minutes BIW during standard of care radiation therapy and QW for the first month after completing standard of care radiation therapy course, and then once monthly for 6 months.

Intervention: Questionnaire Administration

Group B (standard symptom management)

Patients receive standard symptom management QW during standard of care radiation therapy and for 6 months after completing radiation therapy course.

Intervention: Palliative Therapy

Outcomes

Primary Outcomes

Time to first acute care visit

Time Frame: At 3 months

to evaluate the impact of intensive symptom evaluation compared to standard symptom management on time to first acute care visits at 3 months with time to first acute care visits.

Secondary Outcomes

  • Change in Health-related quality of life EORTC QLQ-C30(Baseline to 6 months)
  • Overall survival(Time interval from diagnosis to death from any cause, assessed up to 6 months)
  • Change in financial burden(Baseline to 6 months)
  • Locoregional failure(Time interval from diagnosis to locoregional failure, assessed up to 6 months)
  • Change in caregiver burden(Baseline to 6 months)
  • Time to first acute care visits(At 1 or 6 month)
  • Distant failure(Time interval from diagnosis to distant failure outside head and neck region, assessed up to 6 months)
  • Progression free survival(Time interval from diagnosis to tumor recurrence or progression of disease, assessed up to 6 months)

Study Sites (1)

Loading locations...

Similar Trials